CAR-T therapy has been used successfully in patients with blood cancers such as lymphoma and leukemia. It modifies a patient's own T-cells by adding a piece of an antibody that recognizes unique features on the surface of cancer cells. In a new study, researchers report that they have dramatically broadened the potential targets of this approach - their engineered T-cells attack a variety of solid-tumor cancer cells from humans and mice.
from Latest Science News -- ScienceDaily https://ift.tt/3eLO4Nv
via IFTTT
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment